IL145526A0 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol - Google Patents
Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterolInfo
- Publication number
- IL145526A0 IL145526A0 IL14552600A IL14552600A IL145526A0 IL 145526 A0 IL145526 A0 IL 145526A0 IL 14552600 A IL14552600 A IL 14552600A IL 14552600 A IL14552600 A IL 14552600A IL 145526 A0 IL145526 A0 IL 145526A0
- Authority
- IL
- Israel
- Prior art keywords
- cholesterol
- low density
- density lipoprotein
- lipopritein
- chloesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
PCT/US2000/007870 WO2000057837A2 (fr) | 1999-03-26 | 2000-03-24 | Compositions et procedes agissant sur les taux de cholesterol des lipoproteines de haute densite (hdl) et des apolipoproteines ai, sur les taux de cholesterol des lipoproteines de tres faible densite (vldl) et sur le taux de cholesterol des lipoproteines de faible densite (ldl) |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145526A0 true IL145526A0 (en) | 2002-06-30 |
Family
ID=23060703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14552600A IL145526A0 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
IL145526A IL145526A (en) | 1999-03-26 | 2001-09-20 | Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL145526A IL145526A (en) | 1999-03-26 | 2001-09-20 | Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (fr) |
JP (1) | JP2002540127A (fr) |
KR (2) | KR20050044812A (fr) |
AU (1) | AU776684B2 (fr) |
BR (1) | BR0009333A (fr) |
CA (1) | CA2363486C (fr) |
HK (1) | HK1043309A1 (fr) |
IL (2) | IL145526A0 (fr) |
MX (1) | MXPA01009727A (fr) |
NO (2) | NO331779B1 (fr) |
NZ (2) | NZ514350A (fr) |
WO (1) | WO2000057837A2 (fr) |
ZA (1) | ZA200107598B (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
EP1976567B1 (fr) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Utilisation de transcrits d'arn antisens et non codants naturels comme cibles de médicaments |
KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
RU2620970C2 (ru) | 2008-12-04 | 2017-05-30 | КьюРНА,Инк., | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро |
KR101761424B1 (ko) | 2008-12-04 | 2017-07-26 | 큐알엔에이, 인크. | Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료 |
EP2396038B1 (fr) | 2009-02-12 | 2015-10-21 | CuRNA, Inc. | Traitement des maladies associées au facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du produit antisens naturel de la transcription en bdnf |
ES2656290T3 (es) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2 |
WO2010107740A2 (fr) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1 |
US9155754B2 (en) | 2009-05-06 | 2015-10-13 | Curna, Inc. | Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1 |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010129861A2 (fr) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Traitement de maladies liées à la famille de la dystrophine par inhibition du produit antisens naturel de transcription vers la famille de la dmd |
KR101749356B1 (ko) | 2009-05-18 | 2017-07-06 | 큐알엔에이, 인크. | 재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료 |
EP2432882B1 (fr) | 2009-05-22 | 2019-12-25 | CuRNA, Inc. | Traitement des maladies liées au facteur de transcription e3 (tfe3) et au substrat récepteur d'insuline 2 (irs2) par inhibition du transcript antisens naturel du tfe3 |
WO2010138806A2 (fr) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Traitement de maladies associées à un gène antiviral grâce à l'inhibition d'un produit de transcription antisens naturel d'un gène antiviral |
EP2443238B1 (fr) | 2009-06-16 | 2017-03-22 | CuRNA, Inc. | Traitement de maladies liées à la paraoxonase 1 (pon1) par inhibition d'un produit de transcription antisens naturel à pon1 |
CA2765700C (fr) | 2009-06-16 | 2021-01-05 | Opko Curna, Llc | Traitement de maladies liees au gene du collagene par inhibition d'un produit de transcription antisens naturel a un gene du collagene |
JP6073133B2 (ja) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | 腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療 |
KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
WO2011011700A2 (fr) | 2009-07-24 | 2011-01-27 | Curna, Inc. | Traitement des maladies associées à une sirtuine (sirt) par inhibition du produit de transcription anti-sens naturel chez une sirtuine (sirt) |
JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療 |
WO2011019815A2 (fr) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Traitement de maladies associées à ladiponectine (adipoq) par inhibition du produit de transcription anti-sens naturel dune adiponectine (adipoq) |
EP2467482A4 (fr) | 2009-08-21 | 2013-12-11 | Curna Inc | Traitement des maladies liées à « l'extrémité c de la protéine chip (protéine interagissant avec hsp70) » par inhibition du transcrit antisens naturel de chip |
WO2011031482A2 (fr) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Traitement de maladies associées à la protéine d'activation de gtpase contenant un motif iq (iqgap), par inhibition d'un transcrit antisens naturel de iqgap |
ES2664591T3 (es) | 2009-09-25 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG |
US9173895B2 (en) | 2009-12-16 | 2015-11-03 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 |
CA2782375C (fr) | 2009-12-23 | 2023-10-31 | Opko Curna, Llc | Traitement de maladies associees a la proteine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2 |
WO2011079261A2 (fr) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Traitement de maladies associées au facteur de croissance des hépatocytes (hgf) par inhibition de la transcription antisens naturelle en hgf |
WO2011090741A2 (fr) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Traitement de maladies liées à la protéine tumorale 63 (p63) par l'inhibition du produit de transcription antisens naturel de p63 |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
RU2616283C2 (ru) | 2009-12-31 | 2017-04-13 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
RU2611191C2 (ru) | 2010-01-11 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных со связывающим половые гормоны глобулином (гспг), путем ингибирования природного антисмыслового транскрипта к гспг |
JP5981850B2 (ja) | 2010-01-25 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療 |
CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
RU2612884C2 (ru) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
KR101992076B1 (ko) | 2010-05-03 | 2019-06-21 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP3299464B1 (fr) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Traitement de maladies associées à l'homologue atonal 1 par inhibition du produit de transcription antisens naturel d'atoh1 |
US8980858B2 (en) | 2010-05-26 | 2015-03-17 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
CN109112126B (zh) | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
NO2593547T3 (fr) | 2010-07-14 | 2018-04-14 | ||
CA2813901C (fr) | 2010-10-06 | 2019-11-12 | Curna, Inc. | Traitement de maladies liees a la sialidase 4 (neu4) par inhibition du transcrit anti-sens endogene de neu4 |
US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
WO2012068340A2 (fr) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Compositions d'antagonat et leurs méthodes d'utilisation |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
US9593330B2 (en) | 2011-06-09 | 2017-03-14 | Curna, Inc. | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN |
EP2753317B1 (fr) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | Traitement de maladies liées à des sous-unités alpha de canaux sodiques voltage-dépendants (scnxa) avec de petites molécules |
WO2013138374A2 (fr) | 2012-03-15 | 2013-09-19 | Curna, Inc. | Traitement de maladies associées au facteur neurotrophique dérivé du cerveau (bdnf) par l'inhibition du produit antisens naturel de transcription en bdnf |
CN102628060A (zh) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | 一种低脂奶的生产方法 |
US9695462B2 (en) | 2012-11-05 | 2017-07-04 | Shionogi & Co., Ltd. | Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity |
BR112015022009A2 (pt) | 2013-03-14 | 2017-08-29 | Shionogi & Co | Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular |
TWI688575B (zh) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
CA3209779A1 (fr) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Therapie genique de ceroides-lipofuscinoses neuronales |
EP4378480A1 (fr) * | 2021-07-26 | 2024-06-05 | Purotech Bio, Inc. | Agent anti-virus de l'hépatite b ciblant le facteur hôte lipg |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013791A1 (fr) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes |
CA2273823C (fr) * | 1996-12-06 | 2007-06-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Polypeptides llg de la famille des triacylglycerol lipases, compositions et procedes destines a l'utilisation de ceux-ci dans des hydrolyses enzymatiques, et therapies geniques etprotidiques |
WO1999032611A1 (fr) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | Lipase exprimee dans des cellules endotheliales et procedes d'utilisation associes |
-
2000
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/es active IP Right Grant
- 2000-03-24 CA CA2363486A patent/CA2363486C/fr not_active Expired - Fee Related
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/ko active Search and Examination
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/xx not_active IP Right Cessation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 EP EP00918362A patent/EP1171078A4/fr not_active Ceased
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/ja active Pending
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/fr active IP Right Grant
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/ko not_active IP Right Cessation
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/pt not_active Application Discontinuation
- 2000-03-24 IL IL14552600A patent/IL145526A0/xx unknown
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/xx unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/no not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/zh unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20014657D0 (no) | 2001-09-25 |
CA2363486C (fr) | 2012-12-18 |
NO20100214L (no) | 2001-11-21 |
AU3918700A (en) | 2000-10-16 |
WO2000057837A2 (fr) | 2000-10-05 |
KR20020029651A (ko) | 2002-04-19 |
ZA200107598B (en) | 2003-05-28 |
BR0009333A (pt) | 2002-01-08 |
NZ531180A (en) | 2005-06-24 |
EP1171078A2 (fr) | 2002-01-16 |
HK1043309A1 (zh) | 2002-09-13 |
NO20014657L (no) | 2001-11-21 |
AU776684B2 (en) | 2004-09-16 |
CA2363486A1 (fr) | 2000-10-05 |
NZ514350A (en) | 2004-12-24 |
JP2002540127A (ja) | 2002-11-26 |
NO331779B1 (no) | 2012-03-26 |
MXPA01009727A (es) | 2002-07-22 |
KR100887164B1 (ko) | 2009-03-10 |
KR20050044812A (ko) | 2005-05-12 |
WO2000057837A3 (fr) | 2001-01-25 |
IL145526A (en) | 2010-11-30 |
WO2000057837A8 (fr) | 2001-09-27 |
EP1171078A4 (fr) | 2002-11-06 |
WO2000057837A9 (fr) | 2001-10-18 |
NO331784B1 (no) | 2012-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145526A0 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
EE200300136A (et) | Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks | |
EP1212065A4 (fr) | Compositions et methodes permettant d'augmenter les taux de hdl cholesterol | |
IL140989A0 (en) | Compositions and methods for treating osteoporosis and lowering cholesterol | |
AU2002306930A1 (en) | Plasma processor and method for operating same | |
AU1856997A (en) | Method for raising hdl cholesterol levels | |
IL112593A0 (en) | Methods for inhibiting bone loss and lowering serum cholesterol | |
EP1292603B8 (fr) | Methodes et compositions permettant de traiter le virus de l'hepatite c | |
MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY130670A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
AU3531299A (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | |
AU4446400A (en) | Method and apparatuses for plasma treatment | |
AU5340101A (en) | Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality | |
AU2003204024A1 (en) | Methods for quantitating high-density lipoprotein cholesterol | |
AU6274898A (en) | Bipolar vaporization apparatus and method for arthroscopy | |
AU2002221657A1 (en) | Method and system for preventing the spread of computer viruses | |
DE69931279D1 (de) | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma | |
AU3065999A (en) | Compositions and methods for treatment of asthma | |
AU2001268601A1 (en) | Methods and apparatus for reducing vibrations induced within fan assemblies | |
AU4558799A (en) | Methods and compositions for generating recombinant adeno-associated virus vectors | |
AU2001243614A1 (en) | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol | |
AU7589498A (en) | Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates | |
IL129220A0 (en) | A pharmaceutical composition for lowering plasma levels of lipoprotein (a) | |
EP1089732A4 (fr) | Compositions et methodes de traitement d'une cholesterolemie elevee |